ArticleRadiation oncology journal2026
Investigating prognostic factors of abscopal effect in combined thoracic radiation therapy and immune checkpoint inhibitors for stage IV non-small cell lung cancer.
Article in Radiation oncology journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThis study aimed to identify independent predictors of infield and outfield progression in stage IV non-small cell lung cancer (NSCLC) patients receiving thoracic radiation therapy (RT) combined with immune checkpoint inhibitors (ICI) and evaluate whether local tumor response mediates systemic disease control. MATERIALS AND
methodsThis retrospective study included 98 patients with stage IV NSCLC receiving thoracic RT combined with ICI between January 2018 and December 2023. Infield and outfield progression were analyzed using a competing risk analysis and survival outcomes were estimated using the Kaplan-Meier method.
resultsWith a median follow-up time of 11.2 months (range, 1.4 to 84.4), the median overall survival was 24.9 months (95% confidence interval [CI], 18.4 to 31.3) and the median progression-free survival was 4.5 months (95% CI, 3.5 to 6.7). Infield objective response rate was 77.6%. On multivariable analysis, equivalent doses in 2 Gy fractions ≥40 Gy (subdistribution hazard ratio [SHR], 0.32; p = 0.002), concurrent chemotherapy with ICI (SHR, 0.30; p = 0.005), and squamous histology (SHR, 2.33; p = 0.025) were independent predictors of infield progression. Infield response (SHR, 0.28; p = 0.001), ICI-first sequencing (SHR, 0.27; p = 0.002), and Eastern Cooperative Oncology Group performance status 2 (SHR, 5.32; p < 0.001) independently predicted outfield progression.
conclusionHigher RT dose and infield tumor response independently predicted infield and outfield disease control, consistent with a potential dose-dependent abscopal association in stage IV NSCLC treated with thoracic RT and ICI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.